To date, several clinical cases have reported effective application of inhibitors for treatment of gliomas harboring fusion genes, including lorlatinib for the treatment of SPECC1L-ALK fusion harbouring paediatric high-grade glioma and larotrectinib against EML4-NTRK3 positive recurrent GBM [194, 195]. This evidence concerns the gene ALK and glioblastoma.